ArticleFrontiers in nutrition2025
Development and validation of a nomogram model for predicting postprandial hypertriglyceridemia.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to identify risk factors associated with postprandial hypertriglyceridemia (PHTG) and develop a validated predictive model for its assessment. Methods: We recruited 346 volunteers from the outpatient clinic of Hebei Provincial People's Hospital between January and December 2019. Participants were divided into a model group (January-September 2019, Results: Age, fasting glucose, plasma atherogenic index (AIP), and triglyceride-glucose index (TyG) were identified as independent predictors of PHTG. The developed nomogram model demonstrated strong discriminatory power, with an AUC of 0.894 (95% CI: 0.856-0.931) in the model group and 0.903 (95% CI: 0.842-0.964) in the validation group. The H-L test, DCA, and GiViTI calibration curves confirmed excellent model calibration, demonstrating a robust agreement between predicted and observed outcomes, thus supporting the model's clinical utility. Conclusion: The prediction model developed in this study can serve as an effective tool for predicting PHTG and help identify the high-risk population of PHTG at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.